Shanghai Henlius Biotech, Inc. is a biopharmaceutical company engaged in the research, development, production, and sale of monoclonal antibody drugs and the provision of related technical services. The company's portfolio includes biosimilars and biologics, with key products including serplulimab (HANSIZHUANG), trastuzumab biosimilar (HANQUYOU), rituximab biosimilar (HANLIKANG), denosumab biosimilars (BILDYOS and BILPREVDA), and pertuzumab biosimilar (POHERDY). Its pipeline features antibody-drug conjugates, multispecific antibodies, and small molecules targeting oncology, autoimmune diseases, and ophthalmology. The company operates in markets across China, the United States, Europe, Japan, Australia, and emerging regions in Latin America, Southeast Asia, and the Middle East. It maintains commercial partnerships with international pharmaceutical companies including Abbott, Sandoz, Eisai, and Dr. Reddy's Laboratories. Founded in 2010, the company utilizes a global manufacturing network with GMP-certified facilities in China, Europe, and the United States.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage henlius.com
Sector Healthcare IR page henlius.com/Investor-Presentation.html
Tags
monoclonal antibodies, biosimilars, antibody-drug conjugates, oncology, autoimmune diseases, ophthalmology, small molecules, fusion proteins, biopharmaceuticals, HANSIZHUANG, Hetronifly, HANQUYOU, HERCESSI, Zercepac, Tuzucip, Trastucip, HANLIKANG, BILDYOS, BILPREVDA, TUZEMTY, POHERDY, HLX11, HLX13, HLX14, HLX15, HLX17, HLX18, HLX22, HLX37, HLX43, HLX55, HLX70, HLX71, HLX79, HLX87, HLX97, HLX99, HLX109, HLX04-O, HLX07, Hanjugator, HAI Club
Press page —

Metrics

Valuation  
Market cap HK$ 15.39B
Market cap (USD) $ 1.961B
P/E 25.90
PEG —
P/BV 4.50
P/S 1.76
P/OCF 11.95
P/FCF —
Dividend yield —
Turnover / mcap 0.12%
Returns  
ROE 23.7%
ROI 10.9%
ROIC 10.9%
Profit margin 12.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 87.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 37.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 6.667B 5.724B 5.395B 3.215B 1.682B 587.586M 90.929M 7.421M
Net profit 827.042M 820.47M 546.019M -695.259M -984.052M -993.541M -875.465M -493.686M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 50.99 21.97 14.18 10.86 18.13 37.7 43.89 —
Price performance 12m 1.37 0.56 0.23 -0.43 -0.48 -0.14 — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

NOTICE OF EXTRAORDINARY GENERAL MEETING Bull 0 Bear 0 Routine

Prompts

Shanghai Henlius Biotech, Inc. (ticker 2696), listed in Hong Kong.

ETFs Holding Shanghai Henlius Biotech, Inc.

ETF Weight in ETF Shares Market value As of
AVEE 0.04% 8,900 $ 50.592K Nov 16, 2026
DFSE 0.01% 10,200 $ 64.986K Nov 12, 2026
DFAE 0.00% 41,300 $ 263.131K Nov 12, 2026
DFEM 0.00% 38,700 $ 246.566K Nov 12, 2026
DFAX 0.00% 22,900 $ 145.901K Nov 12, 2026
AVEM 0.00% 16,300 $ 92.657K Nov 16, 2026